Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
12.49
+0.48 (4.00%)
Dec 20, 2024, 4:00 PM EST - Market closed
Replimune Group Employees
Replimune Group had 331 employees as of March 31, 2024. The number of employees increased by 47 or 16.55% compared to the previous year.
Employees
331
Change (1Y)
47
Growth (1Y)
16.55%
Revenue / Employee
n/a
Profits / Employee
-$643,571
Market Cap
941.00M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
The Pennant Group | 5,791 |
Pacira BioSciences | 712 |
Adaptive Biotechnologies | 709 |
Gyre Therapeutics | 593 |
Poseida Therapeutics | 330 |
Zymeworks | 278 |
Liquidia | 145 |
Nuvation Bio | 51 |
REPL News
- 22 days ago - Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch - Seeking Alpha
- 26 days ago - Replimune Announces Pricing of Upsized Public Offering - GlobeNewsWire
- 26 days ago - Replimune Announces Proposed Public Offering - GlobeNewsWire
- 4 weeks ago - Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway - GlobeNewsWire
- 6 weeks ago - Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) - GlobeNewsWire
- 6 weeks ago - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewsWire
- 2 months ago - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire